UBS Group AG Sells 897,094 Shares of Olema Pharmaceuticals, Inc. $OLMA

UBS Group AG reduced its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 75.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 293,560 shares of the company’s stock after selling 897,094 shares during the quarter. UBS Group AG owned approximately 0.43% of Olema Pharmaceuticals worth $7,339,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its holdings in Olema Pharmaceuticals by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after purchasing an additional 477 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Olema Pharmaceuticals by 44.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock worth $96,000 after buying an additional 1,169 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Olema Pharmaceuticals in the 3rd quarter worth $53,000. American Century Companies Inc. purchased a new stake in Olema Pharmaceuticals in the 2nd quarter worth $54,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Olema Pharmaceuticals by 8.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock worth $325,000 after buying an additional 987 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on OLMA shares. HC Wainwright cut their price target on Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Jefferies Financial Group started coverage on Olema Pharmaceuticals in a research note on Thursday, March 19th. They issued a “buy” rating and a $40.00 price target for the company. The Goldman Sachs Group cut their price target on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. JPMorgan Chase & Co. increased their price target on Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 18th. Finally, Stifel Nicolaus started coverage on Olema Pharmaceuticals in a research note on Wednesday, February 11th. They issued a “buy” rating and a $48.00 price target for the company. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.10.

Olema Pharmaceuticals Trading Down 5.1%

Shares of Olema Pharmaceuticals stock opened at $12.90 on Tuesday. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -6.39 and a beta of 2.05. The business has a 50-day moving average price of $15.19 and a 200-day moving average price of $20.55. The company has a quick ratio of 10.88, a current ratio of 10.88 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals, Inc. has a twelve month low of $3.89 and a twelve month high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.52). Equities research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.19 EPS for the current fiscal year.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, insider Shawnte Mitchell sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total transaction of $606,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.56% of the stock is currently owned by insiders.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.